[ad_1]
NEW YORK – Tesis Labs and Personal Genome Diagnostics said on Tuesday they are collaborating to develop new genomic tests for cancer patients that combine results from somatic and germline variants, with the aim of advancing market access and accelerate the adoption of their products.
In an email, PGDx said the companies intend to combine Tesis’ genomic data and reporting capabilities with the somatic variant outputs of certain tissue tests to create a “comprehensive platform that offers patients a streamlined experience … [combining] Germline and somatic variants in a single clinical report. “
The partnership also involves leveraging Tesis’ patient awareness architecture to improve access to genomic sequencing. “There is a growing body of evidence in the literature supporting the clinical value of universally testing all cancer patients for inherited germline risk variants,” PGDx wrote.
Financial terms of the deal were not disclosed.
Tesis offers targeted sequencing tests for a variety of diseases, including hereditary cancer risk tests, through laboratories in Colorado and Texas.
PGDx currently offers three pan-cancer NGS test kits: the FDA-approved Elio Tissue Complete and the Elio Plasma Complete and Elio Plasma Resolve liquid biopsy tests.
“We are delighted to partner with PGDx and leverage our aligned vision and collective expertise to enable new creative clinical opportunities,” said Ron King, CEO of Tesis, in a statement.
“We look forward to working with Tesis Labs to advance advancements in genomic knowledge and patient-centered cancer care,” added Megan Bailey, CEO of PGDx.
Source link
